Role of adenosine deaminase 2 gene variants in pediatric deficiency of adenosine deaminase 2: A structural biological approach Corrigendum in /10.3892/mmr.2021.12128

Zervou,Maria   I.; Goulielmos,George   N.; Matalliotakis,Michail; Matalliotaki,Charoula; Spandidos,Demetrios   A.; Eliopoulos,Elias

doi:10.3892/mmr.2019.10862

Role of adenosine deaminase 2 gene variants in pediatric deficiency of adenosine deaminase 2: A structural biological approach

Corrigendum in: /10.3892/mmr.2021.12128

Authors:
- Maria I. Zervou
- George N. Goulielmos
- Michail Matalliotakis
- Charoula Matalliotaki
- Demetrios A. Spandidos
- Elias Eliopoulos
View Affiliations

Affiliations: Section of Molecular Pathology and Human Genetics, Department of Internal Medicine, School of Medicine, University of Crete, 71003 Heraklion, Greece, Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece, Laboratory of Genetics, Department of Biotechnology, Agricultural University of Athens, 11855 Athens, Greece
Published online on: December 5, 2019 https://doi.org/10.3892/mmr.2019.10862
Pages: 876-882
Copyright: © Zervou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adenosine deaminase 2 (ADA2) belongs to the novel family of adenosine deaminase growth factors (ADGFs), which play an important role in tissue development. The deficiency of adenosine deaminase 2 (DADA2) is a recently recognized autosomal recessive autoinflammatory disease, characterized by various systemic vascular and inflammatory manifestations, which is associated with ADA2 mutations. Considering that a recent screening of an international registry of children with systemic primary vasculitis revealed novel and already known variants in ADA2, this study aimed to further investigate the functional significance of the rare variants detected, namely p.Gly47Arg, p.Gly47Ala, p.Arg8Trp, p.Leu351Gln and p.Ala357Thr, by using a structural biological approach. Three‑dimensional models of the mutants were developed and their three‑dimensional (3D) structures were subjected to detailed interaction and conformational analyses. This led to suggestions that the novel mutations found may affect the formation/stability of the homodimer or may influence the activity of the enzyme. It was thus concluded that the Arg8Trp and Gly47Arg mutations affect the position and interaction of the dimer‑associated HN1 helical structure and therefore, dimer formation and stabilization, while Leu351Gln and Ala357Thr influence the metal coordination in the active site. These findings shed further light onto the structural consequences of the mutations under investigation.

View Figures

View References

1	Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M, et al: Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 370:921–931. 2014. View Article : Google Scholar : PubMed/NCBI
2	Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, et al: Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 370:911–920. 2014. View Article : Google Scholar : PubMed/NCBI
3	Caorsi R, Penco F, Schena F and Gattorno M: Monogenic polyarteritis: The lesson of ADA2 deficiency. Pediatr Rheumatol Online J. 14:512016. View Article : Google Scholar : PubMed/NCBI
4	Francès C, Papo T, Wechsler B, Laporte JL, Biousse V and Piette JC: Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine (Baltimore). 78:209–219. 1999. View Article : Google Scholar : PubMed/NCBI
5	Van Eyck L Jr, Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L, Frans G, Schaballie H, De Hertogh G, Dooley J, et al: Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol. 135:283–287.e5. 2015. View Article : Google Scholar : PubMed/NCBI
6	Ben-Ami T, Revel-Vilk S, Brooks R, Shaag A, Hershfield MS, Kelly SJ, Ganson NJ, Kfir-Erenfeld S, Weintraub M, Elpeleg O, et al: Extending the Clinical Phenotype of Adenosine Deaminase 2 Deficiency. J Pediatr. 177:316–320. 2016. View Article : Google Scholar : PubMed/NCBI
7	Cipe FE, Aydogmus C, Serwas NK, Keskindemirci G and Boztuğ K: Novel mutation in CECR1 leads to deficiency of ADA2 with associated neutropenia. J Clin Immunol. 38:273–277. 2018. View Article : Google Scholar : PubMed/NCBI
8	Westendorp WF, Nederkoorn PJ, Aksentijevich I, Hak AE, Lichtenbelt KD and Braun KP: Unexplained early-onset lacunar stroke and inflammatory skin lesions: Consider ADA2 deficiency. Neurology. 84:2092–2093. 2015. View Article : Google Scholar : PubMed/NCBI
9	Elbracht M, Mull M, Wagner N, Kuhl C, Abicht A, Kurth I, Tenbrock K and Häusler M: Stroke as initial manifestation of adenosinedeaminase 2 deficiency. Neuropediatrics. 48:111–114. 2017.PubMed/NCBI
10	Sahin S, Adrovic A, Barut K, Ugurlu S, Turanli ET, Ozdogan H and Kasapcopur O: Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency. Rheumatol Int. 38:129–136. 2018. View Article : Google Scholar : PubMed/NCBI
11	Bulut E, Erden A, Karadag O, Oguz KK and Ozen S: Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. J Neuroradiol. 46:193–198. 2019. View Article : Google Scholar : PubMed/NCBI
12	Zavialov AV, Gracia E, Glaichenhaus N, Franco R, Zavialov AV and Lauvau G: Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages. J Leukoc Biol. 88:279–290. 2010. View Article : Google Scholar : PubMed/NCBI
13	Zavialov AV and Engström A: Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. Biochem J. 391:51–57. 2005. View Article : Google Scholar : PubMed/NCBI
14	Haskó G, Linden J, Cronstein B and Pacher P: Adenosine receptors: Therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 7:759–770. 2008. View Article : Google Scholar : PubMed/NCBI
15	Meyts I and Aksentijevich I: Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J Clin Immunol. 38:569–578. 2018. View Article : Google Scholar : PubMed/NCBI
16	Wilson DK, Rudolph FB and Quiocho FA: Atomic structure of adenosine deaminase complexed with a transition-state analog: Understanding catalysis and immunodeficiency mutations. Science. 252:1278–1284. 1991. View Article : Google Scholar : PubMed/NCBI
17	Charlab R, Valenzuela JG, Andersen J and Ribeiro JM: The invertebrate growth factor/CECR1 subfamily of adenosine deaminase proteins. Gene. 267:13–22. 2001. View Article : Google Scholar : PubMed/NCBI
18	Gibson KM, Morishita KA, Dancey P, Moorehead P, Drögemöller B, Han X, Graham J, Hancock REW, Foell D, Benseler S, et al PedVas Investigators Network, : Identification of novel adenosine deaminase 2 gene variants and varied clinical phenotype in pediatric vasculitis. Arthritis Rheumatol. 71:1747–1755. 2019. View Article : Google Scholar : PubMed/NCBI
19	Schrödinger LLC: The PyMOL Molecular Graphics System 2016 version 2.2. simplepymol.org/2/support.htmlMarch 5–2019
20	Kinoshita T, Nakanishi I, Terasaka T, Kuno M, Seki N, Warizaya M, Matsumura H, Inoue T, Takano K, Adachi H, et al: Structural basis of compound recognition by adenosine deaminase. Biochemistry. 44:10562–10569. 2005. View Article : Google Scholar : PubMed/NCBI
21	Meyts I, Bosch B, Bolze A, Boisson B, Itan Y, Belkadi A, Pedergnana V, Moens L, Picard C, Cobat A, et al: Exome and genome sequencing for inborn errors of immunity. J Allergy Clin Immunol. 138:957–969. 2016. View Article : Google Scholar : PubMed/NCBI
22	Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M, Conti G, Marchetti F, Picco P, Tommasini A, et al: ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: A multicentre national study. Ann Rheum Dis. 76:1648–1656. 2017. View Article : Google Scholar : PubMed/NCBI
23	Özen S, Batu ED, Taskiran EZ, Özkara HA, Ünal S, Güleray N, Erden A, Karadağ Ö, Gümrük F, et al: A monogenic disease with a variety of phenotypes: deficiency of adenosine deaminase 2. J Rheum. May 1–2019.(Epub ahead of print). View Article : Google Scholar
24	Van Eyck L, Liston A and Wouters C: Mutant ADA2 in vasculopathies. N Engl J Med. 371:4802014.PubMed/NCBI
25	Van Montfrans JM, Hartman EA, Braun KP, Hennekam EA, Hak EA, Nederkoorn PJ, Westendorp WF, Bredius RG, Kollen WJ, Schölvinck EH, et al: Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology (Oxford). 55:902–910. 2016. View Article : Google Scholar : PubMed/NCBI
26	Fellmann F, Angelini F, Wassenberg J, Perreau M, Arenas Ramirez N, Simon G, Boyman O, Demaria O, Christen-Zaech S, Hohl D, et al: IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. J Allergy Clin Immunol. 137:1189–1196.e2. 2016. View Article : Google Scholar : PubMed/NCBI